Evidence analysisNovember 3, 2026Health & Science

Human medicines European public assessment report (EPAR): Vlustozik (previously Ibuprofen Gen.Orph), ibuprofen, Date of authorisation: 16/02/2024, Revision: 5, Status: Authorised

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.

What is established

The European Medicines Agency (EMA) authorized the use of Vlustozik, a generic injectable ibuprofen medicine, on February 16, 2024. This medicine is indicated for treating patent ductus arteriosus (PDA) in premature newborns born before 34 weeks gestational age. PDA is a condition where a critical fetal blood vessel fails to close after birth, leading to heart and lung complications. Since Vlustozik contains the same active ingredient as the reference medicine Pedea, its benefits and risks are considered equivalent. The treatment involves intravenous administration of ibuprofen in three doses at 24-hour intervals under neonatal intensive care supervision.

What the source claims

The EMA webpage states that Vlustozik uses ibuprofen, which reduces prostaglandin levels responsible for keeping the ductus arteriosus open after birth. This pharmacological effect enables the closure of the vessel. The authorization was granted following a review of quality studies for Vlustozik and based on prior clinical evidence supporting Pedea. The product does not require bioequivalence studies since it is administered intravenously and thus directly enters the bloodstream. The medicine’s safety is continuously monitored through pharmacovigilance mechanisms. Healthcare professionals are advised to follow detailed precautions and treatment guidelines to maximize efficacy and minimize risks.

What may be missing from the usual framing

The EMA document focuses primarily on regulatory and clinical efficacy aspects without extensive discussion of broader issues such as accessibility, cost implications of introducing a generic injectable ibuprofen, and potential variation in treatment outcomes across neonatal intensive care units. There is limited contextualization regarding the incidence and long-term outcomes of PDA or how Vlustozik’s availability may influence clinical practice dynamics or healthcare system resource allocation. Information on how this medicine compares to other PDA treatments beyond Pedea is also not provided, nor is there a discussion of potential ethical considerations related to neonatal treatment decisions.

Competing evidence or uncertainty

The primary evidence supporting Vlustozik’s approval rests on abrogating the need for new efficacy trials by referencing the existing data on Pedea, the originator medicine. While this approach is common in generic drug approval, it inherently carries some uncertainty, particularly regarding patient subpopulations or rare adverse effects that may not have been fully characterized in earlier studies. The report does not provide detailed data from independent or post-marketing surveillance studies specific to Vlustozik. Additionally, because ibuprofen modulates prostaglandin pathways, the potential impact on other physiological processes in premature infants remains an area where more targeted research is warranted to ensure safety.

Why it matters

Patent ductus arteriosus presents a significant health challenge in premature infants, contributing to morbidity if untreated. Having an authorized generic intravenous ibuprofen treatment option like Vlustozik increases the availability of a potentially lifesaving intervention within the EU. Such alternatives can reduce costs, promote competition, and potentially improve access in neonatal intensive care settings. However, given the vulnerability of the patient population, ensuring rigorous adherence to guidelines and ongoing safety monitoring remains crucial. The case also illustrates broader regulatory practices on generic medicine authorization by leveraging prior evidence and the balance of clinical benefits versus risks.

What to verify next

  • Obtain and review detailed clinical trial data or observational studies on Vlustozik’s use in real-world neonatal settings to assess safety and efficacy outcomes compared to Pedea.
  • Investigate patient access and cost data to understand the economic impact of introducing Vlustozik in different EU countries.
  • Evaluate pharmacovigilance reports and any updates on adverse effects or recalls linked to Vlustozik since authorization.
  • Examine potential guidelines or expert consensus statements from neonatology societies regarding the preferred PDA treatment options, including generic intravenous ibuprofen.
  • Explore literature on alternative PDA treatments and how they compare mechanistically and clinically with ibuprofen to contextualize treatment choices.

Readers are strongly encouraged to consult the original European Medicines Agency source for the full authorized product information, risk management plan, and pharmaceutical details associated with Vlustozik to form a comprehensive understanding. This article summarizes evidence publicly available as of November 2026 and does not replace professional medical advice.

Source & verification

Primary source: What's new · November 3, 2026

Read the original source

FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.

Continue reading

EudraGMDP database

What is established The EudraGMDP database is an established European Union (EU) information system managed by the European Medicines Agency (EMA). It serves as…